PAT-DANCT06731621
Psilocybin for Treatment-Resistant Depression in Autism
StatusActive, Not Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 5 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 85 words Show 5 more changesShow less
- Primary endpoints: details revised at 2 of 4 entries
- Final enrollment: 18 participants (planned 20)
- Primary and study completion dates: Dec 2026 to Jan 2027
- Secondary endpoints: details revised at 2 of 2 entries
- Study description expanded, about 179 words
- Minor Enrollment closed, study ongoing
- Primary and study completion moved earlier from Aug 2027 to Dec 2026
- Site details revised
Notable Eligibility criteria expanded, about 93 wordsv3 Show 4 more changesShow less
- Primary endpoints: 3 to 4
- Secondary endpoints: 3 to 2
- Study description expanded, about 545 words
- Study title shortened, about 9 words
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Dec 2024 to Nov 1, 2024
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Feasibility of Administering Psilocybin in Conjunction with Psychotherapy in Autistic Adults
Timeframe: From enrollment to end of treatment & follow-up at 12 weeks post-intervention (12 weeks post treatment dosing i.e., Day 0)
Subjective Psychedelic Effects as Measured by the 11-Dimensions of Altered States of Consciousness (11D-ASC) Rating Scale
Timeframe: Administered following each dosing session (Visit 3 (Safety dosing - Day -7)) & Visit 4 (treatment dosing - Day 0))
Number of Participants with Treatment-Related Adverse Events as Assessed by SBQ-ASC & UKU Side Effect Rating Scale
Timeframe: From enrollment to end of treatment & follow-up at 12 weeks post-intervention (12 weeks post treatment dosing i.e., Day 0)
Feasibility of Dense Sampling Brain MRI Procedures & Trial Design
Timeframe: From enrollment to end of treatment & follow-up at 12 weeks post-intervention (12 weeks post-treatment dosing i.e., Day 0)
Secondary (2)
Changes in Brain Network Interactions as Assessed with Pre- and Post-Intervention MRI Brain Scans
Changes & Variance in Brain Functional Connectivity Assessed Across Dense Sampling Brain MRI Sessions
Arms and interventions
Open-labelExperimental
Safety Dosing Session (V3): 10mg of psilocybin + therapy + safety evaluations Active Treatment Session (V4): 25mg of psilocybin + therapy + safety evaluations
Drugs: Psilocybin
Sites
1 site in 1 country
- Centre for Addiction and Mental HealthToronto, Ontario, Canada